{
  "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "docSlug": "2296286e07283457e97b21dc9ce59469",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 46,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide highlights two distinct pipelines: TSTx (Tissue Specific Therapeutics) and NextGen CAR-T.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/3",
  "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "deckJsonHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0.json",
  "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.47,
        "x": 0.02,
        "y": 0.97
      },
      "kind": "disclaimer",
      "text": "Note: NXC-201 is developed by Nexcella, Inc, a 98% owned subsidiary of Immix Biopharma (NASDSAQ:IMMX) as of February 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e076bee7-1784-4c1c-943d-2e328e010344",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "list",
      "text": "NextGen CAR-T Pipeline: Lead cell therapy candidate NXC-201: 58 patients treated best-in-class potential in multiple myeloma and AL amyloidosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05d5cddf-f03b-47e8-984d-35dae131fb60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "list",
      "text": "TSTx Pipeline: Lead TSTx candidate IMX-110 for soft tissue sarcoma and solid tumors combined with anti PD-1 (30 patients treated)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bed6fc5a-ed27-4f7c-99d1-9baec5e3a937",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.87,
        "x": 0.12,
        "y": 0.5
      },
      "kind": "paragraph",
      "text": "Pipeline-in-a-drug potential for both NXC-201 and IMX-110 – registrational studies planned for 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "282d358a-37af-4602-bf16-06448bf312c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.89,
        "x": 0.1,
        "y": 0.41
      },
      "kind": "paragraph",
      "text": "Powered by N-GENIUS Platform for hematologic malignancies + SMARxT Tissue Specific Platform for solid tumors",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a7fecdc-59e8-4aec-a6d4-f4b8327a9ea0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.88,
        "x": 0.11,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "Novel cell therapy and tissue specific therapeutics approaches to oncology and immuno-dysregulated diseases",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be138d17-a64d-42e5-8db5-3d14a5ffeecd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.82,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "IMMIX Biopharma Overview - Personalized Therapies for Oncology and Immunology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "991bf464-371c-450a-8118-502af2ee1e57",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "ec392949-8ab0-475f-b4ad-c8c779b7b23f",
      "evidence": "paragraph/paragraph: Powered by N-GENIUS Platform for hematologic malignancies + SMARxT Tissue Specific Platform for solid tumors",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "250e6c83-38a5-4886-bb70-804cf4659e47",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The presentation identifies the problem and the market opportunity.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}